



## Advances in Pulmonary Drug Delivery, Volume II

Guest Editors:

**Prof. Dr. Carsten Ehrhardt**

School of Pharmacy and  
Pharmaceutical Sciences, Trinity  
College Dublin, Dublin 2, Ireland

**Dr. Ayca Yildiz-Pekoz**

Department of Pharmaceutical  
Technology, Faculty of  
Pharmacy, Istanbul University,  
Beyazıt, Istanbul 34116, Turkey

Deadline for manuscript  
submissions:

**closed (31 July 2022)**

### Message from the Guest Editors

Dear Colleagues,

Drug delivery to the lungs by oral inhalation represents an attractive non-invasive administration route for therapeutics. In addition to locally acting drugs, molecules that are intended to produce a systemic effect can be delivered via the pulmonary route. Pulmonary delivery requires the patient to inhale an aerosol of the therapeutics agent. For the successful delivery via oral inhalation, formulation into an appropriate inhalable dosage form with a sufficient stability is critical. It is also essential that the formulation is paired with a device, which generates an aerosol of the appropriate particle/droplet size to ensure deposition into the desired regions of the respiratory tract.

This Special Issue attempts to highlight current research activities in the areas of inhaler device development; formulation development approaches for inhaled drugs; in vitro and in silico models of pulmonary drug deposition and drug disposition; and advanced delivery options for complex drugs, such as vaccines, antibiotics, nucleic acids, or peptides, to or via the lungs.

Prof. Dr. Carsten Ehrhardt  
Dr. Ayca Yildiz-Pekoz  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma